Intracranial hemorrhage (ICH) in cancer patients treated with bevacizumab : the Memorial Sloan-Kettering experience

Khasraw, M., Holodny, A., Goldlust, S. A. and DeAngelis, L. M. 2012, Intracranial hemorrhage (ICH) in cancer patients treated with bevacizumab : the Memorial Sloan-Kettering experience, Annals of oncology, vol. 23, no. 2, pp. 458-463, doi: 10.1093/annonc/mdr148.

Attached Files
Name Description MIMEType Size Downloads

Title Intracranial hemorrhage (ICH) in cancer patients treated with bevacizumab : the Memorial Sloan-Kettering experience
Author(s) Khasraw, M.ORCID iD for Khasraw, M.
Holodny, A.
Goldlust, S. A.
DeAngelis, L. M.
Journal name Annals of oncology
Volume number 23
Issue number 2
Start page 458
End page 463
Total pages 6
Publisher Oxford University Press
Place of publication Oxford, England
Publication date 2012-02
ISSN 0923-7534
Keyword(s) bevacizumab
intracranial hemorrhage
metastatic brain tumors
primary brain tumors
vascular endothelial growth factor
Summary Background: Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor approved for recurrent glioblastoma (GBM), metastatic breast, colorectal and non-small-cell lung cancers (NSCLC). There has been a potentially increased risk of intracranial hemorrhage (ICH) in patients receiving bevacizumab.

Methods: We retrospectively identified patients with ICH who received bevacizumab between 1 January 2001 and 10 January 2009.

Results: We identified 1024 patients with ICH, 4191 patients who received bevacizumab and 12 (0.3%) who met both our criteria. There were eight women and four men with a median age of 66 years. Primary cancers were ovarian (n = 3), NSCLC (n = 3), colon (n = 1), angiosarcoma (n = 1) and GBM (n = 4). Intracranial tumors were present in 9 of the 12 patients; the remaining three (25%) had no evidence of intracranial pathology. Two hundred and fifty-seven patients with these same primary pathologies and brain tumors were treated with bevacizumab; ICH was seen in nine (3.7%), which was comparable to the 3.6% frequency seen in comparable patients not receiving bevacizumab.

Conclusions: ICH with bevacizumab treatment in this population is rare and does not appear to increase its frequency over the baseline rate of ICH in a comparable population. Most bevacizumab-related ICH occurs into central nervous system tumors but spontaneous hemorrhages were seen.
Language eng
DOI 10.1093/annonc/mdr148
Field of Research 119999 Medical and Health Sciences not elsewhere classified
Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category C1.1 Refereed article in a scholarly journal
Copyright notice ©2011, The Author. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
Persistent URL

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 30 times in TR Web of Science
Scopus Citation Count Cited 42 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 239 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Tue, 31 Jul 2012, 12:24:24 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact